Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.

Lin G, Pankuch G, Appelbaum PC, Kosowska-Shick K.

Antimicrob Agents Chemother. 2014 Oct;58(10):6251-4. doi: 10.1128/AAC.02932-14. Epub 2014 Jul 14.

2.

2012 and beyond: potential for the start of a second pre-antibiotic era?

Appelbaum PC.

J Antimicrob Chemother. 2012 Sep;67(9):2062-8. doi: 10.1093/jac/dks213. Epub 2012 Jun 11. Review.

PMID:
22687888
3.

Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill.

Lin G, Pankuch GA, Appelbaum PC, Kosowska-Shick K.

Diagn Microbiol Infect Dis. 2012 Jul;73(3):287-9. doi: 10.1016/j.diagmicrobio.2012.04.003. Epub 2012 May 8.

PMID:
22575272
4.

Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.

Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC, Kosowska-Shick K.

J Antimicrob Chemother. 2012 Jun;67(6):1321-4. doi: 10.1093/jac/dks069. Epub 2012 Mar 7.

PMID:
22398650
5.

Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin.

Lemaire S, Van Bambeke F, Pierard D, Appelbaum PC, Tulkens PM.

Clin Infect Dis. 2011 Jun;52 Suppl 7:S493-503. doi: 10.1093/cid/cir165.

PMID:
21546626
6.

Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Clark C, McGhee P, Appelbaum PC, Kosowska-Shick K.

Antimicrob Agents Chemother. 2011 May;55(5):2344-51. doi: 10.1128/AAC.01602-10. Epub 2011 Feb 22.

7.

In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.

McGhee P, Clark C, Credito K, Beachel L, Pankuch GA, Appelbaum PC, Kosowska-Shick K.

Antimicrob Agents Chemother. 2011 May;55(5):2417-9. doi: 10.1128/AAC.01672-10. Epub 2011 Feb 22.

8.

Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.

Pankuch GA, Lin G, Kubo A, Armstrong ES, Appelbaum PC, Kosowska-Shick K.

Antimicrob Agents Chemother. 2011 May;55(5):2463-5. doi: 10.1128/AAC.01390-10. Epub 2011 Jan 31.

9.

Time-kill activity of the streptogramin NXL 103 against Gram-positive and -negative bacteria.

Pankuch GA, Lin G, Clark C, Appelbaum PC.

Antimicrob Agents Chemother. 2011 Apr;55(4):1787-91. doi: 10.1128/AAC.01159-10. Epub 2011 Jan 18.

10.

Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint.

Lemaire S, Kosowska-Shick K, Appelbaum PC, Glupczynski Y, Van Bambeke F, Tulkens PM.

J Antimicrob Chemother. 2011 Mar;66(3):596-607. doi: 10.1093/jac/dkq478. Epub 2010 Dec 23.

PMID:
21186193
11.

Rapid detection of vancomycin-non-susceptible Staphylococcus aureus using the spiral gradient endpoint technique.

Doddangoudar VC, O'Donoghue MM, Boost MV, Tsang DN, Appelbaum PC.

J Antimicrob Chemother. 2010 Nov;65(11):2368-72. doi: 10.1093/jac/dkq340. Epub 2010 Sep 16.

PMID:
20851816
12.

Molecular and epidemiologic characteristics of linezolid-resistant coagulase-negative staphylococci at a tertiary care hospital.

Kosowska-Shick K, Julian KG, McGhee PL, Appelbaum PC, Whitener CJ.

Diagn Microbiol Infect Dis. 2010 Sep;68(1):34-9. doi: 10.1016/j.diagmicrobio.2010.05.007.

PMID:
20727467
13.

Spiral gradient endpoint susceptibility testing: a fresh look at a neglected technique.

Pong R, Boost MV, O'Donoghue MM, Appelbaum PC.

J Antimicrob Chemother. 2010 Sep;65(9):1959-63. doi: 10.1093/jac/dkq239. Epub 2010 Jun 30.

PMID:
20595209
14.

Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.

Lemaire S, Kosowska-Shick K, Appelbaum PC, Verween G, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2010 Jun;54(6):2549-59. doi: 10.1128/AAC.01724-09. Epub 2010 Apr 12.

15.

Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Pankuch GA, Seifert H, Appelbaum PC.

Diagn Microbiol Infect Dis. 2010 Jun;67(2):191-7. doi: 10.1016/j.diagmicrobio.2010.01.004. Epub 2010 Mar 24.

PMID:
20338710
16.

Mutant prevention concentrations of four carbapenems against gram-negative rods.

Credito K, Kosowska-Shick K, Appelbaum PC.

Antimicrob Agents Chemother. 2010 Jun;54(6):2692-5. doi: 10.1128/AAC.00033-10. Epub 2010 Mar 22.

17.

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.

Kosowska-Shick K, McGhee PL, Appelbaum PC.

Antimicrob Agents Chemother. 2010 May;54(5):1670-7. doi: 10.1128/AAC.00019-10. Epub 2010 Mar 1.

18.

Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Lin G, Pankuch GA, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2010 May;54(5):2201-5. doi: 10.1128/AAC.01143-09. Epub 2010 Feb 16.

19.

Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.

Lin G, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2010 May;54(5):2258-61. doi: 10.1128/AAC.01350-09. Epub 2010 Feb 9.

20.

Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.

Credito K, Kosowska-Shick K, McGhee P, Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2010 Feb;54(2):673-7. doi: 10.1128/AAC.01353-09. Epub 2009 Dec 14.

21.

In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.

McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC.

Antimicrob Agents Chemother. 2010 Jan;54(1):230-8. doi: 10.1128/AAC.01123-09. Epub 2009 Nov 2.

22.

Postantibiotic effect of ceftaroline against gram-positive organisms.

Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Oct;53(10):4537-9. doi: 10.1128/AAC.00785-09.

23.

Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines.

Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM.

J Antimicrob Chemother. 2009 Nov;64(5):1035-43. doi: 10.1093/jac/dkp267. Epub 2009 Sep 16.

PMID:
19759040
24.

Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.

Kosowska-Shick K, Clark C, Pankuch GA, McGhee P, Dewasse B, Beachel L, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Oct;53(10):4217-24. doi: 10.1128/AAC.00742-09. Epub 2009 Jul 20.

25.

Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains.

Clark C, Kosowska-Shick K, McGhee P, Dewasse B, Beachel L, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Jul;53(7):3118-21. doi: 10.1128/AAC.00183-09. Epub 2009 May 11.

26.

Comparative antipneumococcal activities of sulopenem and other drugs.

Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Jun;53(6):2239-47. doi: 10.1128/AAC.01531-08. Epub 2009 Mar 23.

27.

Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.

Kosowska-Shick K, McGhee P, Appelbaum PC.

Antimicrob Agents Chemother. 2009 May;53(5):2176-80. doi: 10.1128/AAC.01566-08. Epub 2009 Feb 23.

28.

Antianaerobic activity of sulopenem compared to six other agents.

Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2009 May;53(5):2163-70. doi: 10.1128/AAC.01557-08. Epub 2009 Feb 17.

29.

Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.

Clark C, Ednie LM, Lin G, Smith K, Kosowska-Shick K, McGhee P, Dewasse B, Beachel L, Caspers P, Gaucher B, Mert G, Shapiro S, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Apr;53(4):1353-61. doi: 10.1128/AAC.01619-08. Epub 2009 Feb 2.

30.

Postantibiotic effects of telavancin against 16 gram-positive organisms.

Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Mar;53(3):1275-7. doi: 10.1128/AAC.01244-08. Epub 2009 Jan 5.

31.

Postantibiotic effect of tigecycline against 14 gram-positive organisms.

Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Feb;53(2):782-4. doi: 10.1128/AAC.01122-08. Epub 2008 Dec 8.

32.

In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.

Bhagwat SS, McGhee P, Kosowska-Shick K, Patel MV, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Feb;53(2):811-3. doi: 10.1128/AAC.01150-08. Epub 2008 Nov 24. Erratum in: Antimicrob Agents Chemother. 2009 Mar;53(3):1298.

33.

Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains.

Credito K, Lin G, Koeth L, Sturgess MA, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Feb;53(2):814-7. doi: 10.1128/AAC.01132-08. Epub 2008 Nov 17.

34.

Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Kosowska-Shick K, Ednie LM, McGhee P, Smith K, Todd CD, Wehler A, Appelbaum PC.

Antimicrob Agents Chemother. 2008 Dec;52(12):4510-3. doi: 10.1128/AAC.01073-08. Epub 2008 Oct 6.

35.

Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.

Lemaire S, Kosowska-Shick K, Julian K, Tulkens PM, Van Bambeke F, Appelbaum PC.

Clin Microbiol Infect. 2008 Aug;14(8):766-77. doi: 10.1111/j.1469-0691.2008.02035.x.

36.

Molecular characterization of methicillin-resistant Staphylococcus aureus nasal isolates from Turkey.

Kilic A, Mert G, Senses Z, Bedir O, Aydogan H, Basustaoglu AC, Appelbaum PC.

Antonie Van Leeuwenhoek. 2008 Nov;94(4):615-9. doi: 10.1007/s10482-008-9273-8. Epub 2008 Aug 6.

PMID:
18683075
37.

Polymorphism, genetic exchange and intragenic recombination of the aureolysin gene among Staphylococcus aureus strains.

Sabat AJ, Wladyka B, Kosowska-Shick K, Grundmann H, van Dijl JM, Kowal J, Appelbaum PC, Dubin A, Hryniewicz W.

BMC Microbiol. 2008 Jul 29;8:129. doi: 10.1186/1471-2180-8-129.

38.

Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.

Lemaire S, Olivier A, Van Bambeke F, Tulkens PM, Appelbaum PC, Glupczynski Y.

Antimicrob Agents Chemother. 2008 Aug;52(8):2797-805. doi: 10.1128/AAC.00123-08. Epub 2008 Jun 2.

39.

Antistreptococcal activity of AR-709 compared to that of other agents.

Smith K, Ednie LM, Appelbaum PC, Hawser S, Lociuro S.

Antimicrob Agents Chemother. 2008 Jun;52(6):2279-82. doi: 10.1128/AAC.01620-07. Epub 2008 Mar 24.

40.

In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.

Kosowska-Shick K, Clark C, Credito K, Dewasse B, Beachel L, Ednie L, Appelbaum PC.

Antimicrob Agents Chemother. 2008 Feb;52(2):748-52. Epub 2007 Dec 17.

41.

Genotypes of macrolide-resistant pneumococci from children in southwestern Japan: raised incidence of strains that have both erm(B) and mef(A) with serotype 6B clones.

Ikenaga M, Kosowska-Shick K, Gotoh K, Hidaka H, Koga H, Masunaga K, Nagai K, Tsumura N, Appelbaum PC, Matsuishi T.

Diagn Microbiol Infect Dis. 2008 Sep;62(1):16-22. Epub 2007 Dec 18.

PMID:
18068325
42.
43.

Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE.

Drugs. 2007;67(16):2355-82. Review.

PMID:
17983256
44.

Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Pankuch GA, Lin G, Seifert H, Appelbaum PC.

Antimicrob Agents Chemother. 2008 Jan;52(1):333-6. Epub 2007 Oct 29.

45.

Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms.

Starner TD, Shrout JD, Parsek MR, Appelbaum PC, Kim G.

Antimicrob Agents Chemother. 2008 Jan;52(1):137-45. Epub 2007 Oct 22.

46.

In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.

Clark C, Smith K, Ednie L, Bogdanovich T, Dewasse B, McGhee P, Appelbaum PC.

Antimicrob Agents Chemother. 2008 Jan;52(1):77-84. Epub 2007 Oct 15.

47.

Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.

Credito KL, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2008 Jan;52(1):365-73. Epub 2007 Oct 15.

48.

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).

Appelbaum PC.

Int J Antimicrob Agents. 2007 Nov;30(5):398-408. Epub 2007 Sep 20. Review.

PMID:
17888634
49.

Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.

Clark CL, Kosowska-Shick K, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2007 Nov;51(11):4196-201. Epub 2007 Sep 17.

50.

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.

Bogdanovich T, Clark C, Kosowska-Shick K, Dewasse B, McGhee P, Appelbaum PC.

Antimicrob Agents Chemother. 2007 Nov;51(11):4191-5. Epub 2007 Sep 17.

Supplemental Content

Loading ...
Support Center